[{"id":"ca15d8ce-e16c-480b-8a2f-ce77b4af05ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122221","created_at":"2021-11-16T12:53:40.624Z","updated_at":"2024-07-02T16:36:08.200Z","phase":"Phase 1","brief_title":"CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers","source_id_and_acronym":"NCT05122221","lead_sponsor":"Corregene Biotechnology Co., Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CRTE7A2-01 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/17/2022","start_date":" 07/17/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-06-28"}]